Key result
Ergot-derived dopamine agonists did not have a detectable adverse impact on left ventricular ejection fraction compared to non-EDDA treatment in Parkinson patients (63% vs. 65%, ns).
Why the study?
Does ergot-derived dopamine agonist treatment impair left ventricular function in Parkinson patients compared to non-ergot-derived dopamine agonists?
Cross-Sectional (n=110)
Does ergot-derived dopamine agonist treatment impair left ventricular function in Parkinson patients compared to non-ergot-derived dopamine agonists?
Absolute Event Rate: 63% vs 65%
p-value: p=ns
Ergot-derived dopamine agonists do not appear to have a detectable adverse impact on myocardial systolic and diastolic function in Parkinson patients, despite their known association with valvular fibrosis.
No LVEF impairment detected with ergot-derived agonists; supports valve-focused monitoring but leaves open prospective confirmation.
AIMS: Ergot-derived dopamine agonists (EDDA) induce fibrotic heart valve disease. We aimed to investigate whether EDDA treatment also affects left ventricular (LV) function. METHODS AND RESULTS: Myocardial function was evaluated in 110 Parkinson patients [mean age (63.4 +/- 9.0 years)] treated for at least 6 months with either EDDA (n = 71) or non-EDDA (n = 39). LV ejection fraction did not differ between EDDA and non-EDDA patients [63 +/- 4% vs. 65 +/- 4% (ns)]. There was no difference in prevalence of diastolic dysfunction between EDDA and non-EDDA patients [7% vs. 8% (ns)]. Finally, averaged LV systolic myocardial strain and longitudinal displacement analysed by means of two-dimensional speckle tracking showed no difference between EDDA and non-EDDA patients [strain: 19 +/- 3% vs. 19 +/- 2% (ns) and longitudinal displacement: 12 +/- 2 mm vs. 12 +/- 2 mm (ns)]. Elevated p-NT-proBNP was found in 38% of EDDA patients and in 59% of non-EDDA patients (ns). CONCLUSION: In contrast to the well-established association between EDDA treatment and valvular fibrosis, EDDA did not have a detectable adverse impact on myocardial systolic and diastolic function.
No takes yet. Share an insight, caveat, or question.
Rasmussen et al. (2008) conducted a cross-sectional in Parkinson's disease (n=110). Ergot-derived dopamine agonists (EDDA) vs. non-EDDA was evaluated on Left ventricular ejection fraction (p=ns). Ergot-derived dopamine agonists did not have a detectable adverse impact on left ventricular ejection fraction compared to non-EDDA treatment in Parkinson patients (63% vs. 65%, ns).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: